Despite the need for randomized trials, we conclude that RIC allo-SCT from a human leukocyte antigen-identical donor is a potential therapeutic option for acute lymphoblastic leukemia patients aged ≥ 45 years in complete remission and not eligible for MAC allo-SCT. MAC) was not significantly associated with leukemia-free survival (P =. In multivariate analysis, the type of conditioning regimen (RIC vs. At 2 years, LFS was 38% ± 3% (MAC) versus 32% ± 6% (RIC P =. However, to control a Mac above 10.14, enable the screen recording permission by following the below steps. Once the control permission is enabled, you can instantly start controlling the Mac 10.14 Mojave. Now click on the checkbox beside Zoho to enable control permission. 0001, hazard ratio = 1.98) whereas it was associated with higher relapse rate (P =. Select Zoho and click Open to list Zoho in the pane. In a multivariate analysis, nonrelapse mortality was decreased in RIC recipients (P =. With a median follow-up of 16 months, at 2 years, the cumulative incidences of nonrelapse mortality and relapse incidence were 29% ± 2% (MAC) versus 21% ± 5% (RIC P =. This retrospective study assessed the outcome of 576 adult acute lymphoblastic leukemia patients aged ≥ 45 years, and who received a reduced-intensity conditioning (RIC n = 127) or myeloablative conditioning (MAC n = 449) allogeneic stem cell transplantation (allo-SCT) from a human leukocyte antigen-identical sibling while in complete remission.
